AA
XBI icon

AlphaMark Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

AlphaMark Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20
Closed -$1K – 739
2022
Q2 		$1K Buy
+20
New +$1.5K ﹤0.01% 612

Other funds holding XBI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

AlphaMark Advisors's XBI Position: Q3 2022 in Review

AlphaMark Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2022, closing a stake of 20 shares — an estimated $1K sold.

AlphaMark Advisors first reported a position in XBI in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 704 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

  • AlphaMark Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2022 after selling out during the quarter.
  • AlphaMark Advisors sold 20 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $1K.
  • AlphaMark Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 1 quarter.
  • AlphaMark Advisors's State Street SPDR S&P Biotech ETF position peaked at $1K in Q2 2022.
  • 704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on AlphaMark Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.